Limbrel is the first prescription product developed and formulated specifically to safely meet the distinctive nutritional requirements of patients with osteoarthritis through dual inhibition (COX + LOX) of arachidonic acid metabolization and anti-oxidant action rather than COX-2 selective inhibition. Clinical studies have shown Limbrel to be effective in safely managing the unique nutritional needs of osteoarthritis with side effects comparable to placebo.
Limbrel contains flavocoxid, a proprietary blend of natural ingredients from phytochemical food source materials. Flavocoxid is comprised primarily of the flavonoids such as baicalin and catechin. These or similar ingredients can be found in common foods such as soy, peanuts, cauliflower, kale, apples, apricots, cocoa and green tea. The fact that these and similar ingredients have been widely researched and used in medicinal products in other countries also supports biacalin and catechin's safety and effectiveness. Limbrel provides levels of these flavonoids needed to meet the distinctive nutritional requirements of people with osteoarthritis and cannot be obtained through simply changing the diet.
Each capsule of Limbrel provides 250 mg or 500 mg of flavocoxid and each capsule of Limbrel also contains 50 mg of citrated zinc bisglycinate, which provides 10 mg of elemental zinc.
Limbrel is manufactured according to FDA (Food and Drug Administration) current Good Manufacturing Practices (cGMP).
FDA regulations require that Limbrel be used only under a physician's supervision and therefore, it is available by prescription only.